当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.

Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.

Abstract：

:Thirty patients with relapsed pediatric solid tumors received high-dose carboplatin and etoposide with autologous marrow support in a dose-escalation trial. These patients had received extensive prior treatment, which included both cisplatin and etoposide in 25 cases. Six patient cohorts received carboplatin in doses of 1200-2100 mg/m2 and etoposide in doses of 960-1500 mg/m2. All courses were associated with severe neutropenia and thrombocytopenia. The median times from bone marrow infusion to granulocyte recovery (> 0.5 x 10(9)/l) and platelet recovery (> 50 x 10(9)/l) were 33 and 28 days, respectively, with similar findings for all dosage levels. The frequency of non-hematologic toxicities was generally low, although hyponatremia (Na+ < 129 mEq/l) was seen in one-third of the courses. Hepatoxicity was dose-limiting and was significantly associated with the cumulative prior cisplatin dose (p = 0.006). There were four toxic deaths (CNS hemorrhage, alfa-streptococcal sepsis, Candida sepsis, and enterocolitis). Eleven patients received a second course of therapy; toxicity profiles and times to hematologic recovery were similar for the two courses. Clinical responses were observed at all dosage levels. Eleven of 26 evaluable patients achieved a clinical response (one complete, 10 partial). The majority of responses were in patients with neuroblastoma (six of 16) or Hodgkin's disease (two of three). For phase II clinical trials, we recommend dosages of 2100 mg/m2 of carboplatin and 1500 mg/m2 of etoposide for children with prior cumulative cisplatin exposure < 960 mg/m2. This carboplatin dose represents a three- to four-fold increase over pediatric doses tolerated without bone marrow support.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Santana VM,Schell MJ,Williams R,Bowman LC,Thompson EI,Brenner MK,Mirro J Jr

subject

Has Abstract

pub_date

1992-11-01 00:00:00

pages

457-62

issue

5

eissn

0268-3369

issn

1476-5365

journal_volume

10

pub_type

临床试验,杂志文章

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group.

    abstract：:Patients with primary metastatic or recurrent rhabdomyosarcoma (RMS) have a very poor prognosis. Since high-dose chemotherapy (HDC) +/- TBI was thought to improve survival, many centers performed this therapy using different types of hematopoietic rescue (auto BM or PBSC, allo BM). This is a retrospective, multi-cente...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1700628

    authors： Koscielniak E,Klingebiel TH,Peters C,Hermann J,Burdach ST,Bender-Götze C,Müller-Weihrich ST,Treuner J

    更新日期：1997-02-01 00:00:00

  • Urinary trypsin inhibitor concentration can predict the immunological insult of chemotherapy and complications after bone marrow transplantation.

    abstract：:Urinary trypsin inhibitor has attracted attention as an index of the systemic inflammatory response syndrome. In this study, the urine concentration of trypsin inhibitor was measured to compare the immunological insult of conventional chemotherapy and conditioning chemotherapy for bone marrow transplantation. We also ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702755

    authors： Yamada S,Takatsuka H,Takemoto Y,Wada H,Fujimori Y,Okamoto T,Kanamaru A,Kakishita E

    更新日期：2001-01-01 00:00:00

  • Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants.

    abstract：:Graft-versus-tumour reactions as a form of adoptive immunotherapy may help prevent the recurrence of haematological malignancy following allogeneic BMT. We hypothesised that such reactions may be maximised by shortening the duration of post-transplant immunosuppression by a rapid taper of cyclosporine (CYA). CYA dose ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1700961

    authors： Abraham R,Szer J,Bardy P,Grigg A

    更新日期：1997-11-01 00:00:00

  • Hepatic veno-occlusive disease with severe capillary leakage after peripheral stem cell transplantation: treatment with recombinant plasminogen activator and C1-esterase inhibitor concentrate.

    abstract：:Severe veno-occlusive disease (VOD), characterised by elevated serum bilirubin levels, is a known complication in the first 3 weeks after peripheral blood stem cell transplantation (PBSCT). Severe VOD is associated with capillary leakage and multiple organ dysfunction and leads to high mortality. We report a 17-year-o...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701211

    authors： Heying R,Nürnberger W,Spiekerkötter U,Göbel U

    更新日期：1998-05-01 00:00:00

  • Auto-SCT induces a phenotypic shift from CMP to GMP progenitors, reduces clonogenic potential and enhances in vitro and in vivo cycling activity defined by (18)F-FLT PET scanning.

    abstract：:Autologous SCT (auto-SCT) introduces a reduced tolerance to chemotherapy even in patients with adequate engraftment, suggesting long-term effects of the transplantation procedure on the BM capacity. To study the hematopoietic cell compartment after auto-SCT, CD34(+) BM cells (n = 16) from patients at 6-9 months after ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2010.75

    authors： Woolthuis C,Agool A,Olthof S,Slart RH,Huls G,Smid WM,Schuringa JJ,Vellenga E

    更新日期：2011-01-01 00:00:00

  • The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma.

    abstract：:We examined the role of fluorodeoxyglucose-positron emission tomography (FDG-PET) and the addition of involved field radiotherapy (IFRT) as potential modifiers of salvage therapy. From January 2000 to June 2007, 83 patients with chemosensitive relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) underw...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2008.408

    authors： Hoppe BS,Moskowitz CH,Zhang Z,Maragulia JC,Rice RD,Reiner AS,Hamlin PA,Zelenetz AD,Yahalom J

    更新日期：2009-06-01 00:00:00

  • Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man.

    abstract：:Following engraftment of donor hematopoietic cells and induction of host-versus-graft tolerance, immunocompetent lymphocytes of donor origin can induce graft-versus-leukemia (GVL) and graft-versus-tumor (GVT) effects. Engraftment of allogeneic bone marrow cells can be accomplished following non-myeloablative condition...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/sj.bmt.1702356

    authors： Slavin S,Or R,Prighozina T,Gurevitch O,Aker M,Panighari S,Shapira M,Nagler A

    更新日期：2000-05-01 00:00:00

  • Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR.

    abstract：:Allogeneic hematopoietic SCT (allo-HCT) from matched sibling donor (MSD) is recommended for younger patients with intermediate cytogenetic risk AML in first CR (CR1), whereas the role of alternative donor transplants in these patients is unknown. We retrospectively analyzed 605 patients with intermediate-risk AML, who...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2012.84

    authors： Imahashi N,Suzuki R,Fukuda T,Kakihana K,Kanamori H,Eto T,Mori T,Kobayashi N,Iwato K,Sakura T,Ikegame K,Kurokawa M,Kondo T,Iida H,Sakamaki H,Tanaka J,Kawa K,Morishima Y,Atsuta Y,Miyamura K

    更新日期：2013-01-01 00:00:00

  • Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia.

    abstract：:Allogeneic hematopoietic stem cell transplantation (HSCT) can be used to treat children with refractory acute myeloid leukemia (AML). This retrospective analysis aimed to describe the outcomes and risk factors in such children. Data were collected through the nation-wide registry program in Japan. A total of 417 AML (...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/s41409-019-0461-0

    authors： Okamoto Y,Kudo K,Tabuchi K,Tomizawa D,Taga T,Goto H,Yabe H,Nakazawa Y,Koh K,Ikegame K,Yoshida N,Uchida N,Watanabe K,Koga Y,Inoue M,Kato K,Atsuta Y,Ishida H

    更新日期：2019-09-01 00:00:00

  • Combined foscarnet -ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct).

    abstract：:Thirty two allogeneic bone marrow transplant (BMT) recipients, aged 16-55 (median 35), with CMV antigenemia (= > 5 positive cells) developing at a median interval from BMT of 49 days, were given combined treatment with foscarnet and ganciclovir for 15 days. Maintenance was given with foscarnet and ganciclovir on alter...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Bacigalupo A,Bregante S,Tedone E,Isaza A,Van Lint MT,Moro F,Trespi G,Occhini D,Gualandi F,Lamparelli T,Marmont AM

    更新日期：1996-11-01 00:00:00

  • Trajectories of acute graft-versus-host disease and mortality in critically ill allogeneic-hematopoietic stem cell recipients: the Allo-GRRR-OH score.

    abstract：:Acute graft-versus-host disease (aGVHD) is a major cause of morbidity mortality in critically ill hematopoietic stem cell transplantation recipients. We assessed aGVHD trajectories in 191 allogeneic-HSCT recipients (age 42 (27-46)) admitted to our ICU between 2005 and 2015. aGVHD affected 130 (68%) patients (including...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-0857-x

    authors： Pichereau C,Lengliné E,Valade S,Michonneau D,Ghrenassia E,Lemiale V,Socié G,Azoulay E

    更新日期：2020-10-01 00:00:00

  • Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.

    abstract：:High-risk (HR) multiple myeloma (MM) has poor outcomes with conventional therapy. Tandem autologous-non-myeloablative (NMA) allogeneic stem cell transplantation (autologous stem cell transplantation (ASCT)-NMA allogeneic SCT) is potentially curative secondary to graft-versus-myeloma effect. We retrospectively analysed...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2017.37

    authors： Nair AP,Walker P,Kalff A,Bergin K,Hocking J,Avery S,Curtis DJ,Patil S,Das T,Klarica D,Morgan S,Muirhead J,Gorniak M,Reynolds J,Spencer A

    更新日期：2017-06-01 00:00:00

  • Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning.

    abstract：:Graft failure is a major concern after cord blood transplantation (CBT) or HLA-haploidentical transplantation (haplo-SCT). As patients who undergo CBT or haplo-SCT almost always lack both matched-related and -unrelated donors, salvage transplantation would also be limited to either CBT or haplo-SCT. In this study, we ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2011.84

    authors： Yoshihara S,Ikegame K,Taniguchi K,Kaida K,Kim EH,Nakata J,Kato R,Inoue T,Fujioka T,Tamaki H,Okada M,Soma T,Ogawa H

    更新日期：2012-03-01 00:00:00

  • Delayed engraftment and mixed chimerism after HLA-identical sibling donor BMT in Fanconi anaemia.

    abstract：:A 12-year-old girl with Fanconi anaemia (FA) received a bone marrow transplant from her HLA-identical brother following conditioning with cyclophosphamide (20 mg/kg), thoraco-abdominal radiation (TAI) (4 Gy) and equine anti-thymocyte globulin (ATG) (90 mg/kg). Engraftment was delayed and initially tenuous, and was fol...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701855

    authors： Mital MK,Curtis A,Spencer V,Barge D,Skinner R

    更新日期：1999-07-01 00:00:00

  • Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath).

    abstract：:Infectious complications due to adenovirus are of increasing concern after allogeneic stem cell transplantation. Over the past 4 years, we have modified our conditioning regimens to use alemtuzumab in preference to anti-thymocyte globulin (ATG) for pediatric patients receiving stem cell transplants from alternate dono...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705164

    authors： Myers GD,Krance RA,Weiss H,Kuehnle I,Demmler G,Heslop HE,Bollard CM

    更新日期：2005-12-01 00:00:00

  • Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft.

    abstract：:A 51-year-old patient with refractory CLL elected to participate in a trial of nonmyeloablative trans- plantation from an HLA-matched unrelated donor. He received low-dose fludarabine/TBI, with infusion of donor PBPC and cyclosporin (CsA)/MMF. Early post transplant he experienced explosive tumor growth with respirator...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703293

    authors： Nieto Y,Bearman SI,Shpall EJ,Jones RB,Cagnoni PJ,Rabinovitch RA,McSweeney PA

    更新日期：2001-12-01 00:00:00

  • Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.

    abstract：:The underlying plasma cell clones in multiple myeloma (MM) and Ig light-chain amyloidosis (AL) appear to be different not only in terms of 'tumor burden' but also in terms of their underlying biology. High-dose chemotherapy with auto-SCT is one method of reducing the clone size and thereby improving OS. Post-auto-SCT ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2013.53

    authors： Dispenzieri A,Seenithamby K,Lacy MQ,Kumar SK,Buadi FK,Hayman SR,Dingli D,Litzow MR,Gastineau DA,Inwards DJ,Micallef IN,Ansell SM,Johnston PB,Porrata LF,Patnaik MM,Hogan WJ,Gertz MA

    更新日期：2013-10-01 00:00:00

  • Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation.

    abstract：:A retrospective evaluation of 200 consecutive recipients of autologous peripheral blood stem cell transplantation (PBSCT) was conducted to ascertain the incidence and outcome of infection with Clostridium difficile. The diagnosis was confirmed in 14 patients with diarrhea (15 episodes) at a median of 33 days after ste...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701773

    authors： Bilgrami S,Feingold JM,Dorsky D,Edwards RL,Bona RD,Khan AM,Rodriguez-Pinero F,Clive J,Tutschka PJ

    更新日期：1999-05-01 00:00:00

  • Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma.

    abstract：:High-dose melphalan (HDM) has been adopted as standard therapy in the treatment of multiple myeloma. This treatment is associated with non-selective cytotoxicity, causing oral mucositis as the major non-hematological side-effect. Amifostine is a cytoprotector which prevents toxicity induced by anticancer therapy. We p...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1703757

    authors： Thieblemont C,Dumontet C,Saad H,Roch N,Bouafia F,Arnaud P,Hequet O,Espinouse D,Salles G,Roy P,Eljaafari-Corbin A,Du Manoir-Baumgarten C,Coiffier B

    更新日期：2002-12-01 00:00:00

  • Unrelated donor marrow transplantation in children: transplant policy and outcome in Leiden Paediatrics SCT-Centre.

    abstract：:The transplant policy for unrelated donor (UD) BMT at Leiden Paediatrics' SCT-Centre consisted of the use of (1) fully HLA-matched donors or, if not available, HLA-class I matched and/or cytotoxic T-lymphocyte precursor (CTLp)-negative donors and (2) protective isolation of the recipient and antimicrobial suppression ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2009.104

    authors： Vossen JM,Donker AE,Heemskerk MB,Lie JL,van Weel-Sipman MH,Bredius RG,Bakker JD,Egeler RM,Oudshoorn M

    更新日期：2010-01-01 00:00:00

  • Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT.

    abstract：:Posaconazole has been proven to be as effective as fluconazole in the prevention of invasive fungal infections (IFI) in allogeneic haematopoietic SCT patients with GVHD. We assessed, from the perspective of the Spanish National Health Service, the cost-effectiveness of posaconazole vs fluconazole in preventing IFI. A ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2009.272

    authors： de la Cámara R,Jarque I,Sanz MA,Grau S,Casado MA,Sabater FJ,Carreras E

    更新日期：2010-05-01 00:00:00

  • Anti-Müllerian hormone and Inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens.

    abstract：:Serum concentrations of Anti-Müllerian hormone (AMH) and Inhibin B were used to assess potential fertility in survivors of childhood haematopoietic stem cell transplantation (HSCT) after three chemotherapy-conditioning regimens of differing intensity. Of 428 patients transplanted between 1990-2012 for leukaemia and im...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-0866-9

    authors： Leiper A,Houwing M,Davies EG,Rao K,Burns S,Morris E,Laven J,van der Kooi AL,van den Heuvel Eibrink M,Nussey S

    更新日期：2020-10-01 00:00:00

  • Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study.

    abstract：:We conducted a single-arm prospective study in 50 patients who received the combination of an haploidentical stem cell graft and an unrelated umbilical cord blood unit for the treatment of hematological malignancies. The median time for neutrophil engraftment was 13 days (11-20 days), and for platelets was 15 days (11...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2013.154

    authors： Chen J,Wang RX,Chen F,Sun AN,Qiu HY,Jin ZM,Tang XW,Han Y,Fu ZZ,He GS,Miao M,Ma X,Wu DP

    更新日期：2014-02-01 00:00:00

  • Amiodarone and cyclophosphamide: potential for enhanced lung toxicity.

    abstract：:Antineoplastic therapy can be associated with drug-induced lung toxicity. With the increasing use of amiodarone for cardiac dysrhythmias there is an increasing possibility of its combined use with chemotherapies for various malignancies. We report a patient on long-term amiodarone who developed biopsy-proven drug-indu...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703039

    authors： Bhagat R,Sporn TA,Long GD,Folz RJ

    更新日期：2001-05-01 00:00:00

  • Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.

    abstract：:At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU-thiotepa (BU-TTP)-conditioning regimen. We thus performed a retrospective analysis to identify the risk factors for HVOD, which could explain such a ch...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2008.186

    authors： Cacchione A,LeMaitre A,Couanet DV,Benhamou E,Amoroso L,Simonnard N,Hartmann O

    更新日期：2008-10-01 00:00:00

  • Monoclonal rat anti-human lymphocyte antibody Campath-1 binds to T and B lymphocytes but effectively lyses only T cells.

    abstract：:Binding and human complement-mediated T and B lymphocyte lysis were investigated in bone marrow samples obtained from 15 normal donors and 12 patients with a variety of malignant disorders undergoing marrow cryopreservation prior to autologous bone marrow transplantation. All marrow samples were obtained during remiss...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Gazitt Y,Or R,Mumcuoglu M,Slavin S

    更新日期：1987-12-01 00:00:00

  • Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?

    abstract：:Forty-two patients allografted for multiple myeloma after not having attained at least a partial remission (n = 19) or after having experienced disease progression (n = 23) following one autograft were compared with 42 pair-matched controls who underwent salvage autotransplantation under identical conditions. Autograf...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1701208

    authors： Mehta J,Tricot G,Jagannath S,Ayers D,Singhal S,Siegel D,Desikan K,Munshi N,Fassas A,Mattox S,Vesole D,Crowley J,Barlogie B

    更新日期：1998-05-01 00:00:00

  • Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens.

    abstract：:Hematopoietic stem cell transplantation (HSCT) for autoimmune diseases have been, because of safety reasons, overwhelmingly autologous. Results are, in general, encouraging with improvement in quality of life, a remission of up to several years, and perhaps in some diseases improved survival. This indicates that furth...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/sj.bmt.1703950

    authors： Oyama Y,Traynor AE,Barr W,Burt RK

    更新日期：2003-08-01 00:00:00

  • Single dose of filgrastim (rhG-CSF) increases the number of hematopoietic progenitors in the peripheral blood of adult volunteers.

    abstract：:Hematopoietic progenitor cell levels were monitored in the peripheral blood of ten healthy adults receiving a single dose of recombinant human granulocyte colony-stimulating factor (rhG-CSF). The objective was to determine the time and number of progenitor cells released into the peripheral blood, induced by a single ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Schwinger W,Mache C,Urban C,Beaufort F,Töglhofer W

    更新日期：1993-06-01 00:00:00

  • Transplantation of G-CSF mobilized allogeneic peripheral blood stem cells in rabbits.

    abstract：:Mobilized peripheral blood precursor cells (PBPC) are used with increasing frequency to restore autologous hematopoiesis following high-dose radio-chemotherapy. The success of this method has aroused interest in the use of mobilized PBPC for allogeneic transplants. This approach would eliminate the need for marrow asp...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Gratwohl A,Baldomero H,John L,Gimmi C,Pless M,Tichelli A,Nissen C,Filipowicz A,Speck B

    更新日期：1995-07-01 00:00:00